Moderna and Merck's mRNA Melanoma Vaccine Shows 42% Recurrence Risk Reduction in Phase 3 Trial
What happened
Moderna and Merck announced a 42% reduction in melanoma recurrence risk from their personalized mRNA vaccine in a Phase 3 trial.
The Context
- Scientific milestone: The trial validated the potential of individualized neoantigen-targeting therapies, building on mRNA technology proven during COVID-19 vaccine development.
- Investor reaction: Despite positive efficacy data, Moderna shares fell 17-25% as the results did not meet earlier Phase 2 expectations, raising concerns about commercial viability.
- Future plans: Both companies are preparing for regulatory filings and targeting a potential product launch in 2027.
The Number
— This figure represents the reduction in risk of melanoma recurrence or death at a median follow-up of 24.6 months, highlighting the vaccine's potential impact on patient outcomes.
Takeaway
As regulatory processes unfold, the focus will shift to how these findings translate into market opportunities and patient access.
Public health, medical research, healthcare policy, and pharmaceutical developments.
"Dow Jones is a major financial news provider with a professional tone and broad coverage, including specialized health-sector reporting."
— A47 Editor
To the scientific world, Moderna’s cancer vaccine’s results proved that a highly personalized, immune-targeting medication can work. To investors, it didn’t work well enough.
Moderna's stock price fell significantly following the release of study details regarding its mRNA-based cancer vaccine, which raised concerns about its potential market application. Investors reacted negatively to the perceived limitations of the tr...
Public health, medical research, healthcare policy, and pharmaceutical developments.
"Dow Jones is a major financial news provider with a professional tone and broad coverage, including specialized health-sector reporting."
— A47 Editor
Moderna shares plunged after details from a closely guarded mRNA-based cancer vaccine study were shared on social media
Moderna's shares experienced a significant decline after confidential details from a study on its mRNA-based cancer vaccine were leaked on social media ahead of an anticipated conference. The study was expected to provide critical insights into the v...
U.S. business news, corporate developments, and economy.
"The Wall Street Journal is respected for deep financial and economic reporting with a center-right editorial perspective."
— A47 Editor
Moderna’s Stock Plummets After Cancer-Vaccine Data Shared on Social Media
Moderna's stock experienced a significant decline of up to 25% following the unauthorized sharing of data from a closely guarded study regarding its personalized mRNA cancer vaccine. This data was expected to be formally presented at an upcoming conf...
Global business headlines with AI angles.
"General business outlet that frequently covers AI."
— A47 Editor
Details of Moderna's Breakthrough Cancer Vaccine Got Leaked. Its Stock is Plunging.
Moderna's stock plummeted by up to 25% following the leak of data regarding its experimental cancer vaccine, despite the information being more favorable than Wall Street's expectations. This unexpected decline raises concerns about investor confiden...
Business, investment, entrepreneurship, leadership, and innovation.
"Forbes is known for its coverage of business leaders, market trends, and entrepreneurial ventures with a pro-business editorial stance."
— A47 Editor
Moderna Stock Plunges 25% After Possible Cancer Vaccine Data Leak
Moderna's stock plummeted by 25% following a potential data leak regarding its personalized cancer vaccine, marking a significant downturn after a previously strong stock rally in 2026 driven by optimism about the vaccine's prospects.